BIIB 513

structure in first source

Also Known As:

BIIB-513; benzamide, N-(diaminomethylene)-4-(4-(2-furanylcarbonyl)-1-piperazinyl)-3-(methylsulfonyl)-; benzamide-N-(aminoiminomethyl)-4-(4-(2-furanylcarbonyl)-1-piperazinyl)-3-(methylsulfonyl)methanesulfonate

Networked: 6 relevant articles (0 outcomes, 0 trials/studies)

Bio-Agent Context: Research Results

Organic Chemicals: 133
- Hydrocarbons: 1713
  - Acyclic Hydrocarbons
    - Alkanes: 241
      - Alkanesulfonic Acids
        Alkanesulfonates: 9
        Mesylates: 334
        BIIB 513: 6
- Sulfur Compounds: 278
  - Sulfur Acids
    - Sulfonic Acids: 1605
      - Alkanesulfonic Acids
        Alkanesulfonates: 9
        Mesylates: 334
        BIIB 513: 6

Experts

1.	Gross, G J: 3 articles (12/2001 - 05/2000)
2.	Daemmgen, J: 2 articles (10/2000 - 05/2000)
3.	Gumina, R J: 2 articles (10/2000 - 05/2000)
4.	Gross, Garrett J: 1 article (05/2011)
5.	Gumina, Richard J: 1 article (05/2011)
6.	Newman, Peter J: 1 article (05/2011)
7.	Cabreriza, Santos E: 1 article (06/2003)
8.	Coku, Lindita: 1 article (06/2003)
9.	Lacorte, Jared C: 1 article (06/2003)
10.	Mosca, Ralph: 1 article (06/2003)

Related Diseases

1.	Ischemia 06/01/2003 - "In vivo diastolic and postmortem passive left ventricular compliance were reduced after ischemia and reperfusion for control animals but remained unchanged for animals receiving BIIB 513. " 12/01/2001 - "At 30 min of reperfusion, BIIB-513 increased systolic-diastolic LV pressure (LVP) from 49 +/- 2% (controls) to 80 +/- 2% of pre-ischemia values. " 12/01/2001 - "At 2 min of reperfusion, BIIB-513 given before ischemia decreased peak increases in [Na(+)](i) and [Ca(2+)](i), respectively, from 2.5 and 2.3 times (controls) to 1.6 and 1.3 times pre-ischemia values. " 10/01/2000 - "BIIB-513, a selective inhibitor of NHE-1, was infused before ischemia. " 05/19/2000 - "BIIB 513 was infused either prior to ischemia or prior to reperfusion. "
2.	Ventricular Fibrillation 12/01/2001 - "BIIB-513 reduced ventricular fibrillation by 54% and reduced infarct size from 64 +/- 1% to 20 +/- 3%. " 05/19/2000 - "In vivo, NHE-1 inhibition did not affect phase 1a arrhythmias, which occur within the first 10 min of occlusion, however, BIIB 513 significantly reduced the incidence of ischemia-induced phase 1b arrhythmias which occur between 10 and 30 min following occlusion and the incidence of reperfusion-induced ventricular fibrillation. "
3.	Infarction (Infarctions) 12/21/1999 - "In a canine infarct model, either IPC, produced by 1 or four 5-minute coronary artery occlusions, or the specific NHE-1 inhibitor BIIB 513, 0.75 or 3.0 mg/kg, was administered 15 minutes before either a 60- or 90-minute coronary artery occlusion followed by 3 hours of reperfusion. " 12/01/2001 - "BIIB-513 reduced ventricular fibrillation by 54% and reduced infarct size from 64 +/- 1% to 20 +/- 3%. "
4.	Stroke (Strokes) 06/01/2003 - "Preload recruitable stroke work was significantly decreased from baseline after ischemia and reperfusion in the control group (27.7 +/- 2.5 vs 48.0 +/- 5.6 mm Hg [+/- SEM], P =.001) but not in the BIIB 513 group (43.0 +/- 5.8 vs 45.5 +/- 4.1 mm Hg, P = not significant). "
5.	Thrombosis (Thrombus) 05/01/2011 - "For analysis of in vivo thrombus formation, a femoral artery crush injury model was employed and a flow meter was used to monitor the effect of BIIB 513 on cyclic blood flow. "